Abstract
To the Editor: Interferon alfa therapy has been recently proposed1 to treat patients with recurrent hepatitis C virus (HCV) infection following liver transplantation2,3. We report on two patients in whom we believe that interferon alfa therapy (interferon alfa-2b, Schering-Plough) may have triggered acute vanishing bile duct syndrome. Among 28 patients who received liver transplants for cirrhosis due to HCV between 1987 and 1992, serologic (enzyme-linked immunosorbent and recombinant immunoblotting assays), viral (polymerase chain reaction), and histologic evidence of recurrent HCV infection was demonstrated in 21. Interferon alfa therapy (3 million units three times weekly) was instituted in five . . .
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
